Q32 Bio Inc.

Q32 Bio Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Per the National Alopecia Areata Foundation, about 700,000 people in the United States live with alopecia areata, a disease which has a life-altering impact on patients and limited current treatment options. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

Company Details

Employees
31
Founded
-
Address
830 Winter St,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Waltham, Massachusetts
Looking for a particular Q32 Bio Inc. employee's phone or email?

Q32 Bio Inc. Questions

News

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata - PR Newswire

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata PR Newswire

Q32 Bio (NASDAQ: QTTB) completes SIGNAL-AA Part B with 33 patients; topline mid-2026 - Stock Titan

Q32 Bio (NASDAQ: QTTB) completes SIGNAL-AA Part B with 33 patients; topline mid-2026 Stock Titan

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata - WV News

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata WV News

FDA Grants Fast Track Designation to Bempikibart for Alopecia Areata - HCPLive

FDA Grants Fast Track Designation to Bempikibart for Alopecia Areata HCPLive

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer - PR Newswire

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer PR Newswire

Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue - Frontiers

Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue Frontiers

Q32 Bio battered by study failure of immune drug - BioPharma Dive

Q32 Bio battered by study failure of immune drug BioPharma Dive

Q32 Bio (QTTB) Q2 Loss Drops 45% - Nasdaq

Q32 Bio (QTTB) Q2 Loss Drops 45% Nasdaq

Q32 Bio halts trials amid job cuts and pivots to alopecia treatment - Clinical Trials Arena

Q32 Bio halts trials amid job cuts and pivots to alopecia treatment Clinical Trials Arena

Could Q32 Bio’s ‘Skeleton Key’ Open the Door to New Treatments for an Array of Diseases? - CU Anschutz newsroom

Could Q32 Bio’s ‘Skeleton Key’ Open the Door to New Treatments for an Array of Diseases? CU Anschutz newsroom

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday - Yahoo Finance

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday Yahoo Finance

Q32 Bio Trades At Lows While Betting On Immune Breakthroughs - Finimize

Q32 Bio Trades At Lows While Betting On Immune Breakthroughs Finimize

Q32 Bio Closes Merger with Homology Medicines - citybiz

Q32 Bio Closes Merger with Homology Medicines citybiz

Q32 Bio receives Nasdaq noncompliance notice - Investing.com

Q32 Bio receives Nasdaq noncompliance notice Investing.com

Q32 Bio cuts staff, drops renal programme to focus on alopecia drug - FirstWord Pharma

Q32 Bio cuts staff, drops renal programme to focus on alopecia drug FirstWord Pharma

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire

Q32 Bio Inc.'s (NASDAQ:QTTB) largest shareholders are private equity firms with 51% ownership, institutions own 30% - Yahoo Finance

Q32 Bio Inc.'s (NASDAQ:QTTB) largest shareholders are private equity firms with 51% ownership, institutions own 30% Yahoo Finance

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - PR Newswire

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata PR Newswire

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million - PR Newswire

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million PR Newswire

Watkins Advises Homology Medicines in Merger Agreement With Q32 Bio - Latham & Watkins LLP

Watkins Advises Homology Medicines in Merger Agreement With Q32 Bio Latham & Watkins LLP

Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases - PR Newswire

Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases PR Newswire

Q32 Bio sticks with bempikibart but loses staff and phase 2 complement inhibitor - Fierce Biotech

Q32 Bio sticks with bempikibart but loses staff and phase 2 complement inhibitor Fierce Biotech

Q32 Bio Inc. Stock (QTTB) Opinions on Wells Fargo Healthcare Conference Participation - Quiver Quantitative

Q32 Bio Inc. Stock (QTTB) Opinions on Wells Fargo Healthcare Conference Participation Quiver Quantitative

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer - citybiz

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer citybiz

Biotech Slaughtered, Down 76%, On A 'Messy' Update - Investor's Business Daily

Biotech Slaughtered, Down 76%, On A 'Messy' Update Investor's Business Daily

Q32 Bio Appoints Saul Fink as Chief Technology Officer - citybiz

Q32 Bio Appoints Saul Fink as Chief Technology Officer citybiz

Q32 Bio and Homology Medicines Announce Merger Agreement - PR Newswire

Q32 Bio and Homology Medicines Announce Merger Agreement PR Newswire

Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors - PR Newswire

Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors PR Newswire

Q32 Bio in free fall after 'messy' update for bempikibart programme - FirstWord Pharma

Q32 Bio in free fall after 'messy' update for bempikibart programme FirstWord Pharma

Q32 Bio lays off staff, focuses on alopecia program - The Pharma Letter

Q32 Bio lays off staff, focuses on alopecia program The Pharma Letter

Q32 Bio Appoints Jodie Morrison as Acting CEO - citybiz

Q32 Bio Appoints Jodie Morrison as Acting CEO citybiz

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097 (NASDAQ:QTTB) - Seeking Alpha

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097 (NASDAQ:QTTB) Seeking Alpha

Homology enters reverse merger with Q32 Bio - BioPharma Dive

Homology enters reverse merger with Q32 Bio BioPharma Dive

QTTB Stock Price and Chart — NASDAQ:QTTB - TradingView

QTTB Stock Price and Chart — NASDAQ:QTTB TradingView

Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis - PR Newswire

Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis PR Newswire

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug - Stocktwits

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug Stocktwits

Q32 Bio pushes back Phase 2 trial of ADX-097 in AAV patients - ANCA Vasculitis News

Q32 Bio pushes back Phase 2 trial of ADX-097 in AAV patients ANCA Vasculitis News

Top Q32 Bio Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant